ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,821 to 2,840 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)64 of 1,288

48 of 1,303

1.3 points

-0.3 to 2.9

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR)14 of 1,288

3 of 1,303

0.9 points

0.2 to 1.6

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI)57 of 1,288

47 of 1,303

0.8 points

-0.7 to 2.4

2,591NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Rehospitalization66 of 1,288

59 of 1,302

0.6 points

-1.1 to 2.3

2,590NCT02173379

Absorb IV Randomized Controlled Trial

An Informational Packet Regarding Shingles and the HZV vs Standard Medical Care From Their Primary Care Physician: Number of Participants Who Received the Herpes Zoster Vaccine500 of 500

2,089 of 2,089

0.0 points

-0.8 to 0.2

2,589NCT01519570

Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates

Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography18 of 1,288

21 of 1,301

-0.2 points

-1.2 to 0.8

2,589NCT02173379

Absorb IV Randomized Controlled Trial

AC Then T vs AC Then XT: serious adverse events264 of 1,305

200 of 1,283

4.6 points

1.7 to 7.6

2,588NCT00089479

A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer

aTIV (Pooled) vs Licensed TIV: Number of High Risk Subjects With Exacerbation of Preexisting Chronic Disease, Across Vaccine Groups55 of 1,307

48 of 1,281

0.5 points

-1.1 to 2.0

2,588NCT01162122

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

This is Quitting vs Assessment Only Control: Number of Participants With Self-reported 30-day Point Prevalence Abstinence (ITT)314 of 1,304

239 of 1,284

5.5 points

2.3 to 8.6

2,588NCT04251273

Text Message Quit Vaping Intervention for Young Adults

This is Quitting vs Assessment Only Control: Number of Participants With Self-reported 7-day Point Prevalence Abstinence (ITT)440 of 1,304

385 of 1,284

3.8 points

0.2 to 7.3

2,588NCT04251273

Text Message Quit Vaping Intervention for Young Adults

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)71 of 1,286

53 of 1,300

1.4 points

-0.2 to 3.1

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI)66 of 1,286

50 of 1,300

1.3 points

-0.3 to 2.9

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization28 of 1,286

15 of 1,300

1.0 points

0.0 to 2.1

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants withTarget Lesion Revascularization (TLR)16 of 1,286

4 of 1,300

0.9 points

0.3 to 1.7

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR)15 of 1,286

4 of 1,300

0.9 points

0.2 to 1.6

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR)81 of 1,286

65 of 1,300

1.3 points

-0.5 to 3.1

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI67 of 1,286

53 of 1,300

1.1 points

-0.5 to 2.8

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular)5 of 1,286

5 of 1,300

0.0 points

-0.6 to 0.6

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)77 of 1,286

59 of 1,300

1.4 points

-0.3 to 3.2

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)74 of 1,286

55 of 1,300

1.5 points

-0.2 to 3.2

2,586NCT02173379

Absorb IV Randomized Controlled Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=142"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=142

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02173379-d80d7574",
        "title": "Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)",
        "summary": "64 of 1288 against 48 of 1303; risk difference 1.3 points, 95% interval -0.3 to 2.9; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-d80d7574",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2591,
        "risk_difference": {
          "value": 0.012851374992253896,
          "lower": -0.0029005434797239084,
          "upper": 0.028847892149882422
        },
        "group_1": "64 of 1,288",
        "group_2": "48 of 1,303",
        "difference": "1.3 points",
        "interval": "-0.3 to 2.9",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      },
      {
        "id": "NCT02173379-ed34aa5b",
        "title": "Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR)",
        "summary": "14 of 1288 against 3 of 1303; risk difference 0.9 points, 95% interval 0.2 to 1.6; NCT02173379, Absorb IV Randomized Controlled Trial",
        "record": "/library/comparisons/NCT02173379-ed34aa5b",
        "nct_id": "NCT02173379",
        "kind": "outcome",
        "participants": 2591,
        "risk_difference": {
          "value": 0.008567186092295372,
          "lower": 0.0023240775394892726,
          "upper": 0.016016552121647265
        },
        "group_1": "14 of 1,288",
        "group_2": "3 of 1,303",
        "difference": "0.9 points",
        "interval": "0.2 to 1.6",
        "trial_title": "Absorb IV Randomized Controlled Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=143",
  "request_id": "vEibArEgapdfItdj"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?